Answers are grounded in this paper and cite their sources.
Escherichia coli are the main causative agents of uncomplicated urinary tract infection (UTI) and account for >85% of cases of acute cystitis and pyelonephritis, >60% of recurrent cystitis, and at least 35% of recurrent pyelonephritis [1]. The reservoir for uropathogenic E. coli is fecal flora, from which bacteria spread to the urogenital mucosa, ascend into the bladder, and adhere to bladder epithelium. Once established in the bladder, the bacteria multiply and establish a local infection (cystitis) and may further ascend to involve the ureters and kidneys (pyelonephritis). While many factors contribute to the acquisition and progression of E. coli UTI, colonization of the urogenital tract by pathogenic bacteria appears to be a prerequisite for disease [2]. One promising strategy for the prevention of UTI is the development of a vaccine that targets the mechanism(s) by which uropathogens adhere to bladder epithelial cells Earlier studies implicated a role for pilus proteins (fimbriae), the long filamentous protein appendages on the surface of E. coli and in particular type 1 pili, in mediating attachment to host uroepithelial cells [3]. This property appeared to depend on a minor component of type 1 pili, the FimH adhesin. However, the biologic role of FimH of type 1 pili in the pathogenesis of UTIs and its recognition as an important virulence determinant in vivo remained somewhat controversial. This was partly due to the lack of definitive studies with a FimH knockout mutation in a urinary tract isolate of E. coli. Such studies would evaluate the critical role of FimH in colonization in animal models of disease, thereby confirming its function as a virulence determinant. The controversy over recognizing the role of FimH in the pathogenesis of UTIs was also due to the presumption that since type 1 pili and its FimH adhesin are ubiquitous among commensal E. coli and other Enterobacteriaceae and are not unique to uropathogenic E. coli they must serve some function other than being virulence factors. However, while type 1 pili may serve other functions, this does not preclude their ability to play a role in virulence at select sites in the host and/or under the appropriate environmental conditions Recent studies with FimH knockout mutations in uropathogenic E. coli have demonstrated that the FimH adhesin is critical for cystitis to occur in both mouse [4] and nonhuman primate [5] models of disease. Furthermore, FimH interacts specifically with mannosylated glycoproteins (uroplakins) that line the bladder mucosa, leading to bacterial colonization [6]. Aside from its role in colonization, FimH has also been implicated in subsequent stages of pathogenesis, including (1) stimulation of pro-inflammatory cytokines and chemokines by uroepithelial cells [7], leading to neutrophil recruitment and pyuria; (2) induction of uroepithelial cell exfoliation by an apoptosis-like mechanism [8]; and (3) invasion of bladder cells [9] These recent studies on the role of FimH in UTIs are further strengthened by new findings confirming that genes encoding type 1 pili are specifically induced upon inoculation of bacteria into the bladder as a prerequisite for infection. In this regard, it has long been known that bacteria capable of expressing type 1 pili, which includes virtually all E. coli strains, oscillate between a piliated and nonpiliated (bald) phenotype at a high frequency [10]. This is due to flipping of an invertible promoter element that drives transcription of the type 1 pilus genes, a process that is mediated by site-specific recombinases encoded by genes immediately upstream of the type 1 operon. Recent polymerase chain reaction–based studies using primers that flank the invertible promoter element have clearly shown that when nonpiliated bacteria are introduced into the bladder, the promoter is switched to the “on” orientation, allowing for colonization of the bladder mucosa [11]. This would suggest that upon inoculation of bacteria into the bladder from the periurethral area, environmental signals influence type 1 pilus and FimH expression, allowing bacteria to attach and avoid being eliminated by micturition We reasoned that antibodies targeting FimH should prevent UTIs. In addition to blocking attachment at the site of entry and colonization of mucosal surfaces at the earliest stage of the disease process, antibodies against FimH might also promote opsonization of bacteria that have invaded beyond the superficial epithelium for clearance by the systemic immune system. Furthermore, antibodies against the FimH adhesin might also be expected to protect against subsequent bacterial invasion or ascending infection into the kidney. We have now developed FimH as a vaccine candidate against UTI and have tested it in various animal models and surrogate in vitro assays. We have focused our efforts on the development of a recombinant subunit vaccine that contains the FimH adhesin complexed with its cognate chaperone, FimC, which is critical for proper folding and stabilization of the full-length adhesin. The FimC and FimH genes in the vaccine preparation were derived from a well-characterized uropathogenic E. coli isolate, J96 [12] Preliminary studies with the FimCH vaccine candidate were conducted in C3H/HeJ mice, using the purified complex at doses ranging from 0.3 to 30 μg emulsified in complete Freund’s adjuvant. Booster doses were administered in incomplete Freund’s adjuvant. Antibodies to the FimH adhesin were measured in an ELISA-based format using a truncated form of FimH as the capture antigen, which contained the amino-terminal lectin (mannose) binding domain expressed as a histidine-tagged fusion protein (FimH T3) [5]. Mice immunized with FimCH developed high levels of serum IgG directed against FimH T3, which persisted well over a year. In a challenge model utilizing the uropathogenic E. coli strain NU14, >99% reduction in colonization of the bladder mucosa was observed [4] In vitro binding to human tissues, purified receptors, or receptor homologues is often used to elucidate the roles in virulence of many different adhesins, including pilus-associated adhesins. Similarly, assaying for the ability of such antibodies to block attachment of bacteria to cells or specific receptors can assess the functionality of antibodies to adhesins (functional inhibitory titers) We investigated the ability of the anti-FimH adhesin antibodies to block bacterial binding to bladder epithelial cells in vitro, using a flow cytometric method described previously [4]. Sera from vaccinated mice blocked attachment of 50 (94%) of 53 clinical E. coli UTI isolates that were induced to express type 1 pili. Since bacterial strains can express multiple pilus types involved in binding to uroepithelial cells, such as P and S pili, we also tested for the ability of the anti-FimCH antiserum to block binding by strains expressing multiple pilus types simultaneously. A subset of strains induced to express P or S pili (or both) in addition to type 1 pili were also inhibited from attachment to the bladder epithelial cells by the anti-FimCH antiserum. This is an important finding since a single bacterium can often express multiple adhesins with various receptor specificities Our in vitro results suggest that antibodies to the FimH adhesin alone should be able to block such strains from adhering to the bladder. The anti-FimH antiserum also blocked 24 of 24 E. coli strains obtained from women with recurrent UTIs, including multiple isolates from a single individual obtained from sequential infections. In addition, the antiserum blocked attachment of pyelonephritic isolates of E. coli and isolates obtained from women with asymptomatic bacteriuria [4] The previously described preclinical studies in mice involved formulations containing Freund’s adjuvant, which is not suitable for use in humans. The data suggested that protection was dependent upon high-titer IgG responses and therefore a potent formulation suitable for human use would be essential. Additional studies were thus conducted in mice to determine the relative potency of the FimCH antigen adsorbed to alum—A(OH)3— the only adjuvant currently licensed as a component of a vaccine in the United States. As an alternative to alum, the vaccine was adjuvanted with MF59C.1 [13], an oil-in-water (squalene) emulsion developed by Chiron that has been extensively tested in humans and which is approved in Europe and used in an influenza vaccine that has been licensed in Italy. The alum formulation consistently gave titers to FimH in mice that were 5- to 10-fold lower than those seen with Freund’s adjuvant. In contrast, the MF59C.1 formulation gave titers as high as those seen with Freund’s adjuvant. Since the data indicate that there is a relationship between antibody titer to FimH and the ability of the antiserum to block microbial attachment in vitro and infection in vivo, subsequent efforts focused on developing an MF59C.1 formulation Active immunization of mice with FimCH plus MF59.C1 reduced in vivo colonization of the bladder mucosa by uropathogenic E. coli by >99% in the murine cystitis model. Protection was demonstrated with the NU14 cystitis isolate and 5 additional uropathogenic E. coli strains, including strains from women with primary cystitis or recurrent infections. Furthermore, the vaccine protected against in vivo colonization and disease by uropathogenic strains of E. coli capable of expressing multiple adhesins, such as P and S pili, in addition to type 1 pili To confirm that the observed protection was mediated by antibodies to FimH, we challenged naive C3H/HeJ mice with type 1–piliated E. coli strain NU14 after passive, intraperitoneal administration of hyperimmune rabbit anti-FimH antiserum raised against the vaccine. Passive immunization resulted in a 100- to 150-fold reduction in the number of organisms recovered from the bladder 2 days after challenge. Sera from rabbits that had received only adjuvant did not protect at all. Passive protection studies were done with 10 additional strains of uropathogenic E. coli. Significant protection was seen with 9 of the 10 strains tested (P < .01, compared with results for control animals) The murine model for cystitis has proven to be useful in screening vaccine formulations and assessing cross-protection against diverse clinical UTI isolates in vivo. However, it was important to verify the concept of a FimCH vaccine in a nonhuman primate model of UTI prior to initiating clinical trials in humans. Monkeys and humans have similar bladder, ureteral, and renal physiology, and both exhibit natural occurrences of bladder infections and pyelonephritis and vesicoureteral reflux facilitating ascending UTI. Vaccination and challenge studies in the primate model corroborated the original murine studies [5]. Monkeys vaccinated with FimCH plus the MF59C.1 adjuvant developed long-lasting serum IgG antibodies to FimH and functional inhibitory titers. The vaccine protected 3 of 4 vaccinated monkeys from bladder infection by uropathogenic E. coli and from an inflammatory response typically associated with cystitis. Furthermore, there was a direct correlation between the presence of inhibitory antibodies in local (vaginal wash) secretions and protection against colonization and infection A theoretical concern with development of a vaccine that selectively targets E. coli expressing type 1 pili is the potential to alter the normal flora of the gastrointestinal tract. To address this issue, we collected fecal samples before and after immunization of cynomolgus monkeys with the vaccine formulated in MF59C. Overall coliform counts per milliliter of fecal suspension were determined at multiple time points during the study and compared with 3 preimmune samples obtained for each animal. To examine whether vaccination caused a shift in subpopulations within the coliform bacteria, we used a biochemical profile assay for characterization of the fecal samples obtained during the immunization period. No differences in the bacterial populations were observed, suggesting that within the limits of the methodology used, vaccination does not alter the normal gut flora of immunized animals These promising preclinical data provide a strong rationale for further evaluation of the FimCH vaccine and set the stage for initiating controlled clinical trials. A robust manufacturing method yielding a highly characterized recombinant antigen has been developed, a formulation containing an adjuvant suitable for human use has been identified, evidence of protective efficacy in several animal models has been established, and several immunologic end points have been proposed to be evaluated as possible correlates of immune protection. The clinical development of the FimCH vaccine is in progress, and the initial goal is to establish the operational characteristics of the vaccine. Vaccine safety will be a principal focus of the phase I and II program, but selection of an optimal vaccine dose, immunization schedule, and target populations for phase III studies are also key objectives The significant medical and economic burden caused by uncomplicated UTIs in otherwise healthy women makes this population an important target for vaccination. Important clinical development issues are the identification of subgroups at highest risk of developing UTI and the selection of reliable surrogate markers with which to evaluate immune responses. Clearly, women with a history of recurrent UTI are likely to be of greatest interest for efficacy studies, but because the mechanism of action of the vaccine is believed to be mediated through interference with bacterial attachment, the potential impact of vaccination on the syndrome of asymptomatic bacteriuria will also be evaluated. This syndrome, characterized by persistent high-level bacteriuria (>105 cfu/mL) in the absence of clinical symptoms, can lead to the development of symptomatic UTI in otherwise healthy women, but as it does not appear to put this population at increased risk for more severe disease, it is typically not treated when discovered. In contrast, asymptomatic bacteriuria is an important clinical entity during pregnancy and in women with diabetes, in whom it leads to significant morbidity. The impact of vaccination to prevent asymptomatic bacteriuria in these settings should be evaluated. Several other populations have been identified as possible targets for vaccination, including patients with neurogenic bladders, children with UTI and evidence of reflux, and elderly patients with UTI. Each of these populations presents unique clinical development issues that must be addressed, some of which may turn out to be quite complex. Nevertheless, there is growing optimism that an immunologic approach to controlling UTI may soon become a reality and provide an important management alternative to the use of frequent or long-term antibiotics
No takes yet. Share an insight, caveat, or question.
Langermann et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: